{"id":9102,"date":"2021-11-16T07:28:01","date_gmt":"2021-11-16T07:28:01","guid":{"rendered":"http:\/\/cvx.vc\/?p=9102"},"modified":"2021-11-16T07:28:01","modified_gmt":"2021-11-16T07:28:01","slug":"biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer","status":"publish","type":"post","link":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/","title":{"rendered":"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer"},"content":{"rendered":"

V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra V\u00e6kstfonden, Eir Ventures, Strategic Investments, familiekontorer og 70 private investorer. Virksomheden har udviklet l\u00e6gemidlet SYN002, der bek\u00e6mper cytomegalovirus, som er en herpesvirus, og kan vise sig at v\u00e6re livstruende for patienter med nedsat immunforsvar.<\/p>\n

\u00bbDanmark har en global styrkeposition i biotech-industrien, og Synklino er et af resultaterne af denne st\u00e6rke position. Virksomheden er bygget p\u00e5 et \u00e5rti med akademisk forskning af h\u00f8j kvalitet og har et meget kompetent og erfarent team. I V\u00e6kstfonden \u00f8nsker vi at drive innovation, st\u00f8tte den danske biotech-industri og sikre national forankring af vigtige virksomheder. Derfor er vi glade for at v\u00e6re en del af Synklinos rejse<\/em>\u00ab udtaler Lene Gerlach, Investment Manager i V\u00e6kstfonden, i en pressemeddelelse.<\/p>\n

Synklino blev stiftet i 2017 af Thomas Kledal, Mette Rosenkilde og Mads G. Jeppesen og besk\u00e6ftiger i dag seks medarbejdere. Nu skal v\u00e6kstvirksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse. Samtidig skal den nye kapital intensivere udviklingsprogammer for andre l\u00e6gemidler hurtigere end hidtil planlagt.<\/p>\n

L\u00e6s hele pressemeddelelsen her<\/strong><\/em><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.<\/p>\n","protected":false},"author":25,"featured_media":8646,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"yoast_head":"\nBioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer | CVX Ventures<\/title>\n<meta name=\"description\" content=\"V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\" \/>\n<meta property=\"og:locale\" content=\"da_DK\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer\" \/>\n<meta property=\"og:description\" content=\"V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\" \/>\n<meta property=\"og:site_name\" content=\"CVX Ventures\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/cvxventures\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-11-16T07:28:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kim Jessica Axholt\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Skrevet af\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kim Jessica Axholt\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimeret l\u00e6setid\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\"},\"author\":{\"name\":\"Kim Jessica Axholt\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\"},\"headline\":\"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer\",\"datePublished\":\"2021-11-16T07:28:01+00:00\",\"dateModified\":\"2021-11-16T07:28:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\"},\"wordCount\":200,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg\",\"articleSection\":[\"Blogindl\u00e6g\"],\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\",\"url\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\",\"name\":\"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer | CVX Ventures\",\"isPartOf\":{\"@id\":\"https:\/\/cvx.vc\/da\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg\",\"datePublished\":\"2021-11-16T07:28:01+00:00\",\"dateModified\":\"2021-11-16T07:28:01+00:00\",\"description\":\"V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.\",\"breadcrumb\":{\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#breadcrumb\"},\"inLanguage\":\"da-DK\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg\",\"width\":1920,\"height\":1280},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hjem\",\"item\":\"https:\/\/cvx.vc\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cvx.vc\/da\/#website\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"name\":\"CVX Ventures\",\"description\":\"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder\",\"publisher\":{\"@id\":\"https:\/\/cvx.vc\/da\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cvx.vc\/da\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"da-DK\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cvx.vc\/da\/#organization\",\"name\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\",\"url\":\"https:\/\/cvx.vc\/da\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"contentUrl\":\"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg\",\"width\":827,\"height\":394,\"caption\":\"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor\"},\"image\":{\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/cvxventures\/\",\"https:\/\/www.linkedin.com\/company\/cvxventures\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb\",\"name\":\"Kim Jessica Axholt\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"da-DK\",\"@id\":\"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g\",\"caption\":\"Kim Jessica Axholt\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer | CVX Ventures","description":"V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/","og_locale":"da_DK","og_type":"article","og_title":"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer","og_description":"V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.","og_url":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/","og_site_name":"CVX Ventures","article_publisher":"https:\/\/www.facebook.com\/cvxventures\/","article_published_time":"2021-11-16T07:28:01+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg","type":"image\/jpeg"}],"author":"Kim Jessica Axholt","twitter_card":"summary_large_image","twitter_misc":{"Skrevet af":"Kim Jessica Axholt","Estimeret l\u00e6setid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#article","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/"},"author":{"name":"Kim Jessica Axholt","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb"},"headline":"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer","datePublished":"2021-11-16T07:28:01+00:00","dateModified":"2021-11-16T07:28:01+00:00","mainEntityOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/"},"wordCount":200,"commentCount":0,"publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg","articleSection":["Blogindl\u00e6g"],"inLanguage":"da-DK","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/","url":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/","name":"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer | CVX Ventures","isPartOf":{"@id":"https:\/\/cvx.vc\/da\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage"},"image":{"@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage"},"thumbnailUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg","datePublished":"2021-11-16T07:28:01+00:00","dateModified":"2021-11-16T07:28:01+00:00","description":"V\u00e6kstvirksomheden Synklino har rejst 106 mio. kr. fra en r\u00e6kke fonde og 70 private investorer. Nu skal virksomheden bruge den nye kapital til at accelerere l\u00e6gemidlet SYN002 hurtigere frem mod klinisk udvikling og godkendelse.","breadcrumb":{"@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#breadcrumb"},"inLanguage":"da-DK","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/"]}]},{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#primaryimage","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2021\/10\/Synklino.jpg","width":1920,"height":1280},{"@type":"BreadcrumbList","@id":"https:\/\/cvx.vc\/da\/insights\/biotech-selskabet-synklino-rejser-trecifret-millionbelob-fra-bred-vifte-af-investorer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hjem","item":"https:\/\/cvx.vc\/"},{"@type":"ListItem","position":2,"name":"BioTech-selskabet Synklino rejser trecifret millionbel\u00f8b fra bred vifte af investorer"}]},{"@type":"WebSite","@id":"https:\/\/cvx.vc\/da\/#website","url":"https:\/\/cvx.vc\/da\/","name":"CVX Ventures","description":"Vi investerer i Danmarks mest lovende v\u00e6kstvirksomheder","publisher":{"@id":"https:\/\/cvx.vc\/da\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cvx.vc\/da\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"da-DK"},{"@type":"Organization","@id":"https:\/\/cvx.vc\/da\/#organization","name":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor","url":"https:\/\/cvx.vc\/da\/","logo":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/","url":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","contentUrl":"https:\/\/cvx.vc\/wp-content\/uploads\/2022\/08\/Group-241.svg","width":827,"height":394,"caption":"CVX Ventures | Danmarks mest v\u00e6rdiskabende investor"},"image":{"@id":"https:\/\/cvx.vc\/da\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/cvxventures\/","https:\/\/www.linkedin.com\/company\/cvxventures\/"]},{"@type":"Person","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/4cbb55244c8f14962adcd709672339bb","name":"Kim Jessica Axholt","image":{"@type":"ImageObject","inLanguage":"da-DK","@id":"https:\/\/cvx.vc\/da\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/272190fb9f112ece965f1f17765feb31?s=96&d=mm&r=g","caption":"Kim Jessica Axholt"}}]}},"_links":{"self":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/9102"}],"collection":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/comments?post=9102"}],"version-history":[{"count":0,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/posts\/9102\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media\/8646"}],"wp:attachment":[{"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/media?parent=9102"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/categories?post=9102"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cvx.vc\/da\/wp-json\/wp\/v2\/tags?post=9102"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}